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Abstract: 
Although bronchopulmonary manifestations are rare in inflammatory bowel diseases (IBD), subclinical 
abnormalities have been described in up to 50% of cases. The pathophysiology of these abnormalities remains 
unknown. However, a latent inflammation of the bronchial mucosa secondary to the inflammation of the 
intestinal mucosa has been suggested. This subclinical inflammation may lead to increased bronchial 
responsiveness. We studied the bronchial responsiveness in 38 inflammatory bowel disease (IBD) patients, using 
the methacholine test. Bronchial hyperresponsiveness was defined by a PC20M< 16 mg/ml. Twenty-four healthy 
controls were also studied. There was no significant difference in baseline FEV1 between IBD patients and 
controls. However, there was a significantly greater fall in FEV1 in the IBD patients at the concentrations of 
methacholine tested. The frequency of bronchial hyperresponsiveness was significantly higher in the IBD 
population (45%) than in controls (17%; P<0.03). Atopy, defined by skin test, was more common in IBD 
patients (42%) than in controls (21%). Even when only nonatopic subjects were considered, the frequency of 
bronchial hyperresponsiveness was significantly higher in IBD patients (41%) than in controls (5%; P<0.02). 
Thus, subclinical bronchial hyperresponsiveness is common in IBD, and may be considered a further 
extraintestinal manifestation. 
 
Clinical bronchopulmonary manifestations have rarely been described in Crohn's disease (CD) or ulcerative 
colitis (UC) (3,4,11,13). The best known is the hypersensitivity pneumopathy induced by sulfasalazine (17). 
However, subclinical abnormalities are present in about two-thirds of the patients. These abnormalities concern 
both the number and the activity of cells obtained after bronchoalveolar lavage (1) and the functional pulmonary 
parameters such as carbon monoxide-diffusing capacity (1, 6, 8). 
The pathophysiology of these abnormalities is not understood, but the common mucosal immune system has 
been incriminated (4). Lymphocytes stimulated at one site may home back to other mucosal sites. Thus, 
subclinical immune activation and inflammation may exist not only in the gastrointestinal mucosa, but also in all 
mucosae including that of the respiratory tract. Latent inflammation of the bronchial mucosa may lead to 
increased bronchial responsiveness (5). We have studied the bronchial responsiveness in patients with 
inflammatory bowel disease (IBD). Furthermore, we looked at the frequency of atopy, a condition known to 
favor bronchial hyperresponsiveness (2), and one reported, in some studies, to be associated with IBD (7,10). 
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Material and methods 
Patients 
Thirty-eight consecutive patients with IBD were studied (27 CD and 11 UC). These comprised 22 women and 16 
men, 18-62 years old (mean age 33.8 ± 9.5 years). Eleven had a history of clinical manifestation of atopy (five 
with eczema, three with hay fever, and three with both eczema and hay fever). Eighteen were cigarette smokers. 
None had a previous history of pulmonary disease, toxic bronchopulmonary exposure, or sinusitis. None had 
associated diseases such as diabetes mellitus, cardiac failure, or cystic fibrosis. Two patients had a family history 
of asthma. Physical examination and chest radiographs were normal in all patients at the time of the study. 
Duration of the IBD at the onset of the study ranged from 1 month to 20 years (mean duration 59 ± 71 months). 
Among 27 CD patients, five had only small bowel involvement, four had only colon involvement, and 18 had 
both small and large bowel disease or diffuse intestinal involvement. Six had systemic manifestations: arthralgia 
(two), arthritis (two), and erythema nodosum (two). Mean (± SEM) Crohn's disease Activity Index (CDAI) was 
162 ± 129 (0-468). Twelve had active disease (CDAI> 150) at the time of the study. Thirteen were treated with 
5-ASA (0.75-4 g/day), five with methylprednisolone (24-60 mg/day), four with azathioprine (75-150 mg/day), 
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three with azathioprine (0.75-150 mg/day) and methylprednisolone (4-20 mg/day), and two with 
methylprednisolone (16-32 mg/day) and metronidazole (1.5 g/day). 
Among 11 UC patients, seven had total colonic involvement and four limited left-sided colitis. None had 
systemic manifestations. Four had active disease (clinical symptoms and endoscopic lesions). Six were treated 
with 5-ASA (1-3 g/day), one with methylprednisolone (20 mg/day), one with sulfasalazine (2 g/day), and three 
had no treatment. 
Control subjects 
The control group included hospital staff and other healthy volunteers. There were 24 control subjects matched 
for age, sex, and smoking: 14 women and 10 men, 22-40 years old (mean age 25 ± 4.4 years), including 10 
cigarette smokers. One had a familial history of asthma and three had a personal history of clinical manifestation 
of atopy (one had eczema and two had hay fever). 
Atopy 
Atopy was studied with cutaneous prick-testing for classical aeroallergens: Dermatophagoides pteronyssi-nus, 
grass pollen, tree pollen, weed pollen, cat and dog dander, feathers, and molds. Atopy was considered to be 
present if at least one aeroallergen produced a wheal higher than 75% of the histamine control. 
Bronchial responsiveness 
Bronchial responsiveness was measured by metha-choline stimulation. Methacholine chloride solutions 
(biochemicals) were dissolved in saline, stored at 4°C, and used within 14 days of preparation. The aerosols were 
delivered by a nebulizer (Hudson) containing 3 ml of solution and driven by compressed air at 81/min. Under 
these conditions, the nebulizer had an output of 0.3 ml/min and generated an aerosol with particles of 2 µm 
median diameter. After baseline FEV1 measurement, subjects inhaled an aerosolized saline solution by tidal 
breathing for 2 min. FEV1 was measured 3 min after the saline and was considered the control value. Provided 
this FEV1 had not fallen to less than 95% of baseline value, a methacholine challenge was carried out. Subjects 
successively inhaled a methacholine solution of 1, 4, and 16 mg/ml every 3 min. FEV1 was measured 30 and 90 s 
after each concentration from a forced-flow volume curve (Jaeger flow screen). The test was stopped if FEV1 fell 
to less than 80% of the control value recorded. In this case, the PC20M was read from the log dose-response 
curve by linear interpolation. Bronchial hyperresponsiveness was defined as a PC20M less than 16 mg/ml. 
Statistical methods 
Results were expressed as mean ± SEM. The two-tailed t-test or chi-square analysis was used for comparison of 
data between patients and controls. 
Results 
Atopy 
Five out of 24 controls had at least one positive skin reaction, including the three with history of atopy. The 
frequency of the positive reactions was as follows: D. pteronyssinus (4/5), tree pollen (3/5), grass pollen (1/5), 
and molds (1/5). There were several positive reactions in three subjects. Sixteen out of 38 IBD patients had at 
least one positive reaction with the prick test, including the 11 with history of atopy. The frequency of positive 
tests was as follows: grass pollen (8/16), D. pteronyssinus (7/16), cat dander (7/ 16), tree pollen (6/16), feathers 
(3/16), dog dander (2/16), weed pollen (2/16), and molds (2/16). Eleven patients were simultaneously reactive to 
more than one aeroallergen. Thus, the proportion of atopy tended to be higher in the IBD group than in the 
control group (P < 0.10). 
Bronchial responsiveness 
There was no significant difference in basal FEV1 between patients and controls (98 + 1.99% of predicted value 
in control vs 102 ± 1.3% in IBD). The mean fall in FEV1 in patients and controls is shown in Fig. 1. FEV1 fell by 
6.11 ±0.99% (n = 38) and 1.31 ± 0.96% (n = 24) after 1 mg/ml of methacholine (P<0.002), 11.7±1.58% (n = 37) 
and 5.7±1.17% (n = 24) after 4 mg/ml of methacholine (P< 0.008), and 14.8 ±1.41% (n = 29) and 11.84 ± 1.48 
(n = 23) after 16 mg/ml of methacholine (P< 0.06) in patients and controls, respectively. The number of patients 
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tested with 4 and 16 mg/ml was smaller than with 1 mg/ml because some had already had a fall > 20 % in FEV1. 
The frequency of bronchial hyperrespon-siveness (PC20M< 16 mg/ml) was significantly higher in IBD patients 
(17/38) than in controls (4/ 24) (P<0.03). Mean PC20M in patients with bronchial hyperresponsiveness was 7.04 
± 1.21 mg/ml vs 9.4 ± 2.48 mg/ml in controls with bronchial hyperresponsiveness (P<0.2). 
 
Fig. 1. Fall in FEV1 (mean ± SEM) after inhalation of 1, 4, and 16 mg/ml of methacholine in IBD patients (■) 
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The frequency of bronchial hyperresponsiveness, and the fall in FEV1 after 4 mg/ml of methacholine were 
compared in different subgroups of controls and patients. Bronchial hyperresponsiveness was significantly 
associated with atopy in the controls: 3/5 atopic control subjects had bronchial hyperresponsiveness vs 1/19 
nonatopic (P<0.02). In contrast, atopy was not significantly associated with bronchial hyperresponsiveness in 
IBD: 8/16 atopic IBD patients vs 9/22 nonatopic had bronchial hyperresponsiveness. The mean fall in FEV1 after 
4 mg/ml of methacholine in atopic control subjects (10.1 ± 3.6%) was significantly greater than in nonatopic 
subjects (4.51 ± 1.04%) (P<0.05). In contrast, there was no significant difference between atopic (10.5 ± 2.2%) 
and nonatopic (12.62 ± 2.25%) IBD patients. Considering only the nonatopic subjects in each group, the mean 
falls in FEV1 were 5.86 ±1.01% (n = 21)and 1.91 ± 0.76% (n=19)after 1 mg/ml of methacholine (P< 0.004), 
12.62 ± 2.25 % (n = 21) and 4.51 ± 1.04% (n = 19) after 4 mg/ml of methacholine (P< 0.004) (Fig. 2), and 13.29 
± 1.58% (n= 16), and 9.94 ± 1.42% (n = 19) after 16 mg/ml of methacholine (P<0.12) in patients and controls, 
respectively. The proportion of bronchial hyperresponsiveness in nonatopic IBD patients (9/22) was significantly 
higher than that in nonatopic controls (1/ 19) (P<0.02). The mean value of PC20M in IBD patients with bronchial 
hyperresponsiveness was 6.74 ± 1.61 mg/ml vs 13.9 mg/ml in the unique control showing bronchial 
hyperresponsiveness (Fig. 3). 
Age and sex did not influence the frequency of bronchial hyperresponsiveness or the mean fall in FEV1 after 4 
mg/ml of methacholine in either patients or controls. 
Smoking did not influence the frequency of bronchial responsiveness in either patients or controls. However, 
there was a trend to a greater fall in FEV1 after 4 mg/ml of methacholine in smokers compared to nonsmokers 
both in patients (15.18 ± 2.79% vs 9.24 ± 1.62%) (P = 0.ll) and controls (9.52 ± 1.8 vs 5.21 ± 1.3 %) (P = 0.06). 
Considering only nonatopic nonsmoker subjects in each group, there was a still greater decrease in FEV1 after 
methacholine in patients than in controls. The mean falls in FEV1 were, respectively, 4.4 ± 0.9% (n = -10) and 
0.5 ± 1.1% (n = 10) after 1 mg/ml of methacholine (P<0.02), 9.4 ± 2.6% (n = 10) and 4.3 ± 1.3% (n = 10) after 4 
mg/ml of methacholine (P = 0.1), and 12.9 ± 2.4% (n = 9) and 7.2 ± 1.6% (n = 10) after 16 mg/ml of 
methacholine (P = 0.06). 
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Neither the proportion of bronchial hyperresponsiveness nor the mean fall in FEV1 after 4 mg of methacholine 
was significantly different between UC (4/11; 11.9 ± 2.8%) and CD (13/27; 12.5 ± 1.8%). Furthermore, these 
two parameters were not influenced by the activity of the disease at the moment of the test, its extent, or its 
duration. However, in CD, the mean fall in FEV1 after 4 mg/ml of metha-choline tended to be greater in patients 
with extraintestinal manifestations of the disease (18.5 ± 5.6%) than in patients without (9.4 ±1.8%) (P = 0.06), 
and it was significantly greater in patients treated with azathioprine (21.8 ± 5.6% vs 9± 1.4%) (P<0.003). There 
was no significant difference between patients treated with corticosteroids (12.7 ± 3.6%) and other patients (11.4 
± 2.2%). 
Discussion 
This study shows increased bronchial responsiveness to methacholine in patients with IBD who had no clinical 
pulmonary symptoms, normal chest roentgenograms, and normal basal FEV1 measurements. Indeed, 45% of 
IBD patients had a PC20M smaller than 16 mg/ml vs 17% of control subjects, and the mean fall in FEV1 after 
various concentrations of methacholine was greater in patients than in controls. This hyperresponsiveness, 
although definite, was small compared with previous measurements in mild asthmatic subjects (12). 
Although mild pulmonary impairments have been previously demonstrated in IBD, most studies have failed to 
find any difference in basal FEV1 between IBD and control subjects (1, 6, 8). Our study confirms the absence of 
difference in basal bronchial caliber between the two groups. However, bronchial responsiveness evaluation is a 
more sensitive method to detect mild airway dysfunction. As well as in asthma, increased bronchial 
responsiveness has been described in sinusitis, various bronchopulmonary diseases, toxic bronchopulmonary 
exposure, diabetes, and cardiac failure (2). These conditions were not present in our patients. 
Bronchial hyperresponsiveness has also been described in association with a family history of asthma. However, 
the two patients with a family history of asthma in our study did not have bronchial hyperresponsiveness. There 
was no significant difference in bronchial responsiveness between atopic and nonatopic IBD patients, and the 
difference between IBD patients and controls was still noted if only nonatopic patients were considered. The 
presence of atopy was determined by skin reaction because it is the more specific method (14). We did not 
measure the serum IgE levels, and some patients treated by oral steroids may have had false negative skin tests. 
However, among the patients treated with steroids (n=11) and having negative skin test (n = 6), only two had 
bronchial hyperresponsiveness, which could have been associated with undiscovered atopy. Patients and controls 
were matched for smoking. Moreover, there was only a mild, nonsignificant difference in the bronchial 
responsiveness in both patients and controls between smokers and nonsmokers. This may be due to the fact that 
both controls and patients were young and had only a relatively short exposure to tobacco. Considering only 
nonatopic, nonsmoker subjects in each group, there was still a greater decrease in FEV1 after various 
concentrations of methacholine in patients than in controls. 
Thus, our study demonstrates that IBD, by itself, favors the development of nonspecific airway hyper-
responsiveness. The significance of this phenomenon is not clear. There is strong evidence in the literature of the 
relationship between airway inflammation and bronchial hyperresponsiveness (5). Inflammation of the small 
airways may occur in IBD, induced by the bronchial homing of lymphocytes activated in the digestive tract. 
Alveolar lymphocytosis has been previously described in CD, although not in UC (1). In this perspective, the 
histopathology of the bronchial mucosa remains to be investigated. Neither the type of IBD nor the extent or 
activity of disease at the time of study influenced bronchial responsiveness. However, there was a trend to 
increased bronchial responsiveness in CD patients with extraintestinal manifestations. As recent genetic studies 
in IBD suggest disease heterogeneity to be important (15), patients with extraintestinal manifestations may 
represent a particular subgroup of CD patients. Bronchial responsiveness was also significantly increased in CD 
patients treated with azathioprine. These patients had chronic active disease and may also represent a subgroup 
of patients more prone to develop bronchial hyperresponsiveness. However, a side-effect of azathioprine could 
not be excluded since pneumopathies have been described with this drug (16). Although no decrease in bronchial 
responsiveness in patients treated with steroids was noted in our study, most of them were treated with relatively 
low doses, which have been shown to be unable to influence bronchial responsiveness (9). 
In conclusion, this study has demonstrated increased bronchial responsiveness in IBD patients with no 
bronchopulmonary symptoms. This increase occurs independently of the presence of atopy, and may be a 
consequence of activation of the mucosal immune system. Further studies to elucidate the mechanism that 
sustains this functional abnormality and to confirm the stronger association with some subgroups of IBD are 
planned. 
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